Uy Ear
Stock Analyst at Mizuho Securities
(2.54)
# 2,884
Out of 4,402 analysts
578
Total ratings
39.7%
Success rate
1%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Uy Ear
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TECX Tectonic Therapeutic | Reiterated: Buy | $85 | $29.49 | +188.23% | 34 | Jun 10, 2026 | |
| ALKS Alkermes | Reiterated: Buy | $53 | $44.92 | +17.99% | 57 | Jun 9, 2026 | |
| RNAC Cartesian Therapeutics | Reiterated: Buy | $40 | $8.06 | +396.28% | 28 | Jun 9, 2026 | |
| EOLS Evolus | Reiterated: Buy | $15 | $6.51 | +130.41% | 48 | Jun 8, 2026 | |
| MBX MBX Biosciences | Reiterated: Buy | $57 | $37.25 | +53.02% | 10 | Jun 4, 2026 | |
| ARQT Arcutis Biotherapeutics | Reiterated: Buy | $35 | $24.59 | +42.33% | 161 | Jun 3, 2026 | |
| INAB IN8bio | Reiterated: Buy | $4 | $1.44 | +177.78% | 16 | Jun 1, 2026 | |
| RLMD Relmada Therapeutics | Reiterated: Buy | $19 | $6.52 | +191.41% | 36 | May 14, 2026 | |
| ACAD ACADIA Pharmaceuticals | Reiterated: Buy | $35 | $21.39 | +63.63% | 38 | May 7, 2026 | |
| SRPT Sarepta Therapeutics | Reiterated: Buy | $31 | $15.00 | +106.67% | 63 | May 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $35 | $26.82 | +30.50% | 25 | May 5, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $146 → $175 | $162.71 | +7.55% | 38 | Dec 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $1.22 | n/a | 13 | Aug 18, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $3.01 | n/a | 9 | Aug 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Hold | $14 | $3.63 | n/a | 1 | Jul 10, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Hold | $14 | $34.56 | n/a | 1 | Jul 10, 2019 |
Tectonic Therapeutic
Jun 10, 2026
Reiterated: Buy
Price Target: $85
Current: $29.49
Upside: +188.23%
Alkermes
Jun 9, 2026
Reiterated: Buy
Price Target: $53
Current: $44.92
Upside: +17.99%
Cartesian Therapeutics
Jun 9, 2026
Reiterated: Buy
Price Target: $40
Current: $8.06
Upside: +396.28%
Evolus
Jun 8, 2026
Reiterated: Buy
Price Target: $15
Current: $6.51
Upside: +130.41%
MBX Biosciences
Jun 4, 2026
Reiterated: Buy
Price Target: $57
Current: $37.25
Upside: +53.02%
Arcutis Biotherapeutics
Jun 3, 2026
Reiterated: Buy
Price Target: $35
Current: $24.59
Upside: +42.33%
IN8bio
Jun 1, 2026
Reiterated: Buy
Price Target: $4
Current: $1.44
Upside: +177.78%
Relmada Therapeutics
May 14, 2026
Reiterated: Buy
Price Target: $19
Current: $6.52
Upside: +191.41%
ACADIA Pharmaceuticals
May 7, 2026
Reiterated: Buy
Price Target: $35
Current: $21.39
Upside: +63.63%
Sarepta Therapeutics
May 6, 2026
Reiterated: Buy
Price Target: $31
Current: $15.00
Upside: +106.67%
May 5, 2026
Reiterated: Buy
Price Target: $35
Current: $26.82
Upside: +30.50%
Dec 12, 2025
Maintained: Hold
Price Target: $146 → $175
Current: $162.71
Upside: +7.55%
Aug 18, 2023
Rated: Hold
Price Target: n/a
Current: $1.22
Upside: n/a
Aug 11, 2023
Rated: Hold
Price Target: n/a
Current: $3.01
Upside: n/a
Jul 10, 2019
Initiated Coverage: Hold
Price Target: $14
Current: $3.63
Upside: n/a
Jul 10, 2019
Initiated Coverage: Hold
Price Target: $14
Current: $34.56
Upside: n/a